
NFlection Therapeutics Announces Orphan Drug Designation of NFX-179
WAYNE, PA — NFlection Therapeutics, Inc. recently announced that the Food and Drug Administration (FDA) has granted the company orphan drug designation for NFX-179 for the treatment of cutaneous neurofibromatosis …
NFlection Therapeutics Announces Orphan Drug Designation of NFX-179 Read More